Slow Uptake of HiSeq, Reduced Reagent Use Take Toll on Illumina's Revenues | GenomeWeb

By Monica Heger

This story was originally published Oct. 7.

Illumina this week warned that its third-quarter revenues would be lower than previously forecast due to an uncertain academic funding environment, slower-than-expected uptake of the HiSeq 2000, and reduced reagent use for its sequencing instruments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.